A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)

Inclusion Criteria:

• Adult patients, >/= 18 years of age

• Active moderate to severe rheumatoid arthritis (RA)

• On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable doseof at least 15 mg/week for at least 6 weeks

• Oral corticosteroids must have been at stable dose of </= 10 mg/day prednisone (orequivalent) for at least 25 out of 28 days prior to first dose of study drug

• Body weight </= 150 kg

Exclusion Criteria:

• Major surgery (including joint surgery) within 8 weeks prior to screening or plannedmajor surgery within 6 months of study entry

• Rheumatic autoimmune disease other than RA

• Functional class IV according to American College of Rheumatology (ACR) classification

• Prior history of or current inflammatory joint disease other then RA

• Treatment with traditional DMARDs other than methotrexate within 1 month (forleflunomide 3 months) prior to baseline

• Treatment with any biologic drug that is used in the treatment or RA

• Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline

• Known active current or history of recurrent infection

• History of or currently active primary or secondary immunodeficiency

• Positive for HIV